Only about 40% of extensive-stage SCLC patients reach second-line therapy. Amgen and AstraZeneca are moving Imdelltra earlier
Amgen’s Phase 3 DeLLphi-305 trial met its primary overall survival endpoint with Imdelltra plus Imfinzi as first-line maintenance in extensive-stage small cell lung cancer.